Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Sol-Gel Technologies (NASDAQ: SLGL) to present at H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023.
08/30/2023 - 08:00 AM
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.
Presentation Information
Event: H.C. Wainwright 25th Annual Global Investment Conference Time: Presentation to be accessible on-demand, beginning 7:00 AM EDT, Monday, September 11, 2023 Presenter: Alon Seri-Levy, Chief Executive Officer Format: Virtual presentation Registration: Link
About Sol-Gel Technologies
Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to and commercialized by Galderma in the U.S.
The Company’s pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 for the treatment of rare skin keratodermas, which had positive results in a Phase 1 study.
For additional information, please visit www.sol-gel.com .
For further information, please contact:
Investors:
Irina Koffler Investor relations, LifeSci Advisorsikoffler@lifesciadvisors.com +1 917 734 7387
Sol-Gel Technologies
Gilad Mamlok Chief Financial Officergilad.mamlok@sol-gel.com
SLGL Rankings
#5200 Ranked by Stock Gains
SLGL Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
Country
Israel
City
7 Golda Meir
About SLGL
sol-gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. our lead product candidates, vered for the treatment of papulopustular rosacea and twin and sirs-t for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. this technology consists of microcapsules made of silica. based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs. our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. this creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. our delivery system also enables to produce novel fixed-dose combinations th